ArrowMark Colorado Holdings LLC Has $13.28 Million Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

ArrowMark Colorado Holdings LLC reduced its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 12.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 531,286 shares of the company’s stock after selling 77,582 shares during the period. ArrowMark Colorado Holdings LLC’s holdings in Kiniksa Pharmaceuticals were worth $13,277,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Braidwell LP boosted its stake in Kiniksa Pharmaceuticals by 40.6% in the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after purchasing an additional 836,210 shares in the last quarter. FMR LLC lifted its position in Kiniksa Pharmaceuticals by 36,925.0% during the 3rd quarter. FMR LLC now owns 696,810 shares of the company’s stock worth $17,413,000 after buying an additional 694,928 shares in the last quarter. Millennium Management LLC lifted its position in Kiniksa Pharmaceuticals by 159.8% during the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after buying an additional 382,539 shares in the last quarter. Rubric Capital Management LP grew its holdings in Kiniksa Pharmaceuticals by 10.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after acquiring an additional 223,094 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Kiniksa Pharmaceuticals by 31.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after acquiring an additional 157,741 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Price Performance

KNSA opened at $21.85 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $16.47 and a fifty-two week high of $28.15. The firm has a 50 day simple moving average of $23.95 and a 200 day simple moving average of $22.98.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same period last year, the company earned ($0.20) EPS. The business’s revenue for the quarter was up 67.4% compared to the same quarter last year. Analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total value of $437,325.00. Following the sale, the chief operating officer now directly owns 116,975 shares in the company, valued at approximately $2,923,205.25. This trade represents a 13.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 54.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on KNSA. JPMorgan Chase & Co. upped their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Evercore ISI upped their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.